Implications of the REACH registry for vascular surgery;Implicaciones del registro REACH para la cirugía vascular

Medicina Clinica

Volumn 132, Issue SUPPL. 2, 2009, Pages 25-29

  Álvarez Fernández, Luis Javier ^a   Vallina Victorero Vázquez, Manuel Javier ^a   Gallo, María José Ramos ^a   Santiago, María Vicente ^a  

^a HOSPITAL DE CABUEÑES   (Spain)

Author keywords

Atherosclerosis; Peripheral arterial disease; Prevalence; Prophylaxis; Risk factors; Treatment

Indexed keywords

ANTITHROMBOCYTIC AGENT; CILOSTAZOL; HEMATOLOGIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ARTERY DISEASE; BLOOD PRESSURE REGULATION; BLOOD RHEOLOGY; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; DRUG USE; EXERCISE; GERIATRIC CARE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; PERIPHERAL VASCULAR DISEASE; PREVALENCE; REVASCULARIZATION; RISK FACTOR; SHORT SURVEY; SMOKING; SMOKING CESSATION; SPAIN; VASCULAR SURGERY;

AGED; ATHEROSCLEROSIS; FEMALE; HUMANS; MALE; MYOCARDIAL INFARCTION; REGISTRIES; STROKE; THROMBOSIS; VASCULAR DISEASES; VASCULAR SURGICAL PROCEDURES;

EID: 68349131413     PISSN: 00257753     EISSN: 15788989     Source Type: Journal    
DOI: 10.1016/S0025-7753(09)71749-X     Document Type: Article

References (47)

1. A. Martín, J.M. Ortega, R. Fernández, M.C. Fernández, and F. Vaquero Frecuentación por patología vascular en atención primaria Angiología 57 2005 237 242
2. J. Dormandy, M. Mahir, G. Ascady, F. Balsano, P. de Leeuw, and P. Blomberg Fate of the patient with chronic leg ischaemia J Cardiovasc Surg 30 1989 50 57
3. W.G. Hughson, J.I. Mann, and A. Garrod Intermittent claudication: prevalence and risk factors Br Med J 1 1978 1379 1381
4. A. Reunanen, H. Takkunen, and A. Aromaa Prevalence of intermittent claudication and its effect on mortality Acta Med Scand 211 1982 249 256
5. I.G. de Backer, M. Kornitzer, J. Sobolski, and H. Denolin Intermittent claudication: epidemiology and natural history Acta Cardiol 34 1979 115 124
6. H.E.J.H. Stoffers, V. Kaiser, and J.A. Knottnerus Prevalence in general practice F.G.R. Fowkes Epidemiology of peripheral vascular disease 1991 Springler-Verlag London 109 115
7. W.C.S. Smith, M. Woodward, and H. Tunstall-Pedoe Intermittent claudication in Scotland F.G.R. Fowkes Epidemiology of peripheral vascular disease 1991 Springler-Verlag London 117 124
8. S. Novo, G. Avellone, V. di Garbo, M.G. Abrignani, M. Liquori, and A.V. Panno Prevalence of risk factors in patients with peripheral arterial disease: a clinical and epidemiological evaluation Int Angiol 11 1992 218 229
9. F.G.R. Fowkes, E. Housley, E.H. Cawood, C.C. Macintyre, C.V. Ruckley, and R.J. Prescott Edimburgh artery study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population Int J Epidemiol 20 1991 384 392
10. C. Diehm, A. Schuster, J.R. Allenberg, H. Darius, R. Haberl, and S. Lange High prevalence of peripheral arterial disease and co-morbility in 6880 primary care patients: cross-sectional study Atherosclerosis 172 2004 95 105 (Pubitemid 38058606)
11. I. Vicente, C. Lahoz, M. Taboada, A. García, M.A. San Martín, and I. Perol Prevalencia de un índice tobillo/brazo patológico según el riesgo cardiovascular calculado mediante la función de Framingham Med Clin (Barc) 124 2005 641 644
12. M. Aranzazu Miguel Gómez, I. López Rodríguez, and J. Machín Fernández Prevalencia de arteriopatía periférica no diagnosticada en población mayor de 64 años mediante la determinación del índice tobillo-brazo Cad Aten Primaria 12 2005 202 205
13. E. Puras Mallagray, M.A. Cairols Castellote, and F. Vaquero Morillo Estudio piloto de prevalencia de la enfermedad arterial periférica en atención primaria Angiología 58 2006 119 125
14. M.J. Vallina-Vázquez, F. Vaquero-Lorenzo, A. Álvarez- Salgado, M.J. Ramos Gallo, M. Vicente-Santiago, and J. García Estudio de prevalencia de isquemia crónica de miembros inferiores y de aneurisma de aorta abdominal en mayores de 65 años Angiología 59 2007 225 235
15. J.A. Dormandy, and J.B. Rutherford Management of peripheral arterial disease (PAD). TASC Working Group. Transatlantic Inter-Society Consensus (TASC) J Vasc Surg 31 2000 S14
16. A. da Silva, L.K. Widmer, H.W. Ziegler, C. Nissen, and W. Schweiger The Basle longitudinal study; report on the relation of initial glucose level to baseline ECG abnormalities, peripheral artery disease, and subsequent mortality J Chron Dis 32 1979 797 803
17. W.S. Aronow, and C. Ahn Prevalence of coexistence of coronary artery disease, peripheral arterial disease, and atherothrombotic brain infarction in men and women > or = 62 years of age Am J Cardiol 74 1994 64 65 (Pubitemid 24196317)
18. M. Ögren, B. Hedblad, S.O. Isacsson, L. Janzon, G. Junqquist, and S.E. Lindell Ten year cerebrovascular morbidity and mortality in 68-year-old men with asymptomatic carotid stenosis BMJ 310 1995 1294 1298
19. G.C. Leng, A.J. Lee, F.G. Fowkes, M. Whiteman, J. Dunbar, and E. Housley Incidence, natural history and cardiovascular events in symptomatic and asymptomatic peripheral arterial disease in the general population Int J Epidemiol 25 1996 1172 1181 (Pubitemid 27013522)
20. R. Cui, H. Iso, K. Yamagishi, T. Tanigawa, H. Imano, and T. Ohira Relationship of smoking and smoking cessation with ankle-to-arm blood pressure index in elderly Japanese men Eur J Cardiovasc Prev Rehabil 13 2006 243 248 (Pubitemid 44097730)
21. Y.W. Chi, and M.R. Jaff Optimal risk factor modification and medical management of the patient with peripheral arterial disease Catheter Cardiovasc Interv 71 2008 475 489
22. DCCT Research Group Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial Am J Cardiol 75 1995 894 903
23. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insuline compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 352 1998 837 853
24. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560-72.
25. G.C. Leng, J.F. Price, and R.G. Jepson Lipid-lowering for lower limb atherosclerosis Cochrane Database Syst Rev 4 2007 CD000123
26. D.H. Blankenhorn, S.P. Azen, D.W. Crawford, S.A. Nesim, M.E. Sanmarco, and R.H. Selzer Effects of colestipol-niacin therapy on human femoral atherosclerosis Circulation 83 1991 438 447
27. A.A. Kroon, W.N. van Asten, and A.F. Stalenhoef Effect of apheresis of low-density lipoprotein on peripheral vascular disease in hypercholesterolemic patients with coronary artery disease Ann Intern Med 125 1996 945 954
28. B. Lewis Randomised controlled trial of the treatment of hyperlipidemia on progression of atherosclerosis Acta Med Scand Suppl 701 1985 53 57
29. H. Buchwald, H.R. Bourdages, C.T. Campos, P. Nguyen, S.E. Williams, and J.R. Boen Impact of cholesterol reduction on peripheral arterial disease in the Program on The Surgical Control of the Hyperlipidemias (POSCH) Surgery 120 1996 672 679
30. T.R. Pedersen, J. Kjekshus, K. Pyorala, A.G. Olsson, T.J. Cook, and T.A. Musliner Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S) Am J Cardiol 81 1998 333 335
31. S. Mondillo, P. Ballo, R. Barbati, F. Guerrini, T. Ammaturo, and E. Agricola Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease Am J Med 114 2003 359 364
32. W.S. Aronow, D. Nayak, S. Woodworth, and C. Ahn Effect of simvastatin versus placebo on treadmill exercise time until the onset of intermittent claudication in older patients with peripheral arterial disease at six months and at one year after treatment Am J Cardiol 92 2003 711 712
33. E.R. Mohler III, W.R. Hiatt, and M.A. Creager Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease Circulation 108 2003 1481 1486
34. L.A. Bazzano, K. Reynolds, K.N. Holder, and J. He Effect of folic acid supplementation on risk of cardiovascular diseases: A meta-analysis of randomized controlled trials JAMA 296 2006 2720 2726
35. N.W. Shammas Epidemiology, classification, and modificable risk factors of peripheral arterial disease Vasc Health Risk Manag 3 2007 229 234
36. D. Mukherjee, and J.S. Yadav Update on peripheral vascular diseases: from smoking cessation to stenting Cleve Clin J Med 68 2001 723 733
37. Antithrombotic Trialists' Collaboration Collaborative metaanalysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients BMJ 324 2002 71 86
38. L. Janzon, D. Bergqvist, J. Boberg, M. Boberg, I. Eriksson, and F. Lindgarde Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study J Intern Med 227 1990 301 308
39. C.L. Bennett, P.D. Weinberg, K. Rozenberg-Ben-Dror, P.R. Yarnold, H.C. Kwaan, and D. Green Thrombotic thrombocytopenic purpura associated with ticlopidine. A review of 60 cases Ann Intern Med 128 1998 541 544 (Pubitemid 28177661)
40. C.L. Bennett, J.M. Connors, J.M. Carwile, J.L. Moake, W.R. Bell, and S.R. Tarantolo Thrombotic thrombocytopenic purpura associated with clopidogrel N Engl J Med 342 2000 1773 1777
41. CAPRIE Steering Committee A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) Lancet 348 1996 1329 1339
42. D.L. Bhatt, K.A. Fox, W. Hacke, P.B. Berger, H.R. Black, W.E. Boden CHARISMA Investigators Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events N Engl J Med 354 2006 1706 1717
43. nd, J.D. Martin, and E.B. Bortey A comparison of cilostazol and pentoxifylline for treating intermittent claudication Am J Med 109 2000 523 530
44. K. Schrör The pharmacology of cilostazol Diabetes Obes Metab 4 Suppl 2 2002 S14 S19
45. C. Suárez, M. Cairols, J. Castillo, E. Esmatjes, J. Sala, and X. Llobet Control de factores de riesgo y tratamiento de la aterotrombosis. Registro REACH España Med Clin 129 2007 446 450
46. D.L. Bhatt, P.G. Steg, E.M. Omán, A.T. Hirsch, Y. Ikeda, J.L. Mas REACH Registry Investigators International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis JAMA 295 2006 180 189
47. C. Shearman Implications of REACH for the vascular specialist The Bristish Journal of Cardiology 14 Suppl 3 2007 S9 S10